Lifecore Biomedical Stock Current Valuation
| LFCR Stock | 6.55 0.03 0.46% |
Valuation analysis of Lifecore Biomedical helps investors to measure Lifecore Biomedical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 03/23/2025, Enterprise Value Over EBITDA is likely to drop to 9.18. In addition to that, Enterprise Value Multiple is likely to drop to 9.18. Fundamental drivers impacting Lifecore Biomedical's valuation include:
Overvalued
Today
Please note that Lifecore Biomedical's price fluctuation is moderately volatile at this time. Calculation of the real value of Lifecore Biomedical is based on 3 months time horizon. Increasing Lifecore Biomedical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Lifecore stock is determined by what a typical buyer is willing to pay for full or partial control of Lifecore Biomedical. Since Lifecore Biomedical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lifecore Stock. However, Lifecore Biomedical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.55 | Real 5.53 | Target 8.5 | Hype 6.55 | Naive 6.67 |
The intrinsic value of Lifecore Biomedical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lifecore Biomedical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lifecore Biomedical helps investors to forecast how Lifecore stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lifecore Biomedical more accurately as focusing exclusively on Lifecore Biomedical's fundamentals will not take into account other important factors: Lifecore Biomedical Company Current Valuation Analysis
Lifecore Biomedical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Lifecore Biomedical Current Valuation | 364.22 M |
Most of Lifecore Biomedical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lifecore Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lifecore Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Lifecore Biomedical is extremely important. It helps to project a fair market value of Lifecore Stock properly, considering its historical fundamentals such as Current Valuation. Since Lifecore Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lifecore Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lifecore Biomedical's interrelated accounts and indicators.
Click cells to compare fundamentals
Lifecore Current Valuation Historical Pattern
Today, most investors in Lifecore Biomedical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lifecore Biomedical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Lifecore Biomedical current valuation as a starting point in their analysis.
Lifecore Biomedical Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Lifecore Biomedical has a Current Valuation of 364.22 M. This is 97.46% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 97.81% higher than that of the company.
Lifecore Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lifecore Biomedical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lifecore Biomedical could also be used in its relative valuation, which is a method of valuing Lifecore Biomedical by comparing valuation metrics of similar companies.Lifecore Biomedical is currently under evaluation in current valuation category among its peers.
Lifecore Biomedical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lifecore Biomedical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lifecore Biomedical's managers, analysts, and investors.Environmental | Governance | Social |
Lifecore Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0247 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 364.22 M | ||||
| Shares Outstanding | 37.03 M | ||||
| Shares Owned By Insiders | 4.52 % | ||||
| Shares Owned By Institutions | 73.59 % | ||||
| Number Of Shares Shorted | 2.4 M | ||||
| Price To Book | 15.69 X | ||||
| Price To Sales | 1.85 X | ||||
| Revenue | 128.26 M | ||||
| Gross Profit | 45.64 M | ||||
| EBITDA | 35.6 M | ||||
| Net Income | 9.33 M | ||||
| Total Debt | 130.36 M | ||||
| Book Value Per Share | 0.42 X | ||||
| Cash Flow From Operations | (217 K) | ||||
| Short Ratio | 19.93 X | ||||
| Earnings Per Share | (0.56) X | ||||
| Price To Earnings To Growth | 3.51 X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 524 | ||||
| Beta | 0.97 | ||||
| Market Capitalization | 242.52 M | ||||
| Total Asset | 273.7 M | ||||
| Retained Earnings | (166.52 M) | ||||
| Working Capital | 42.16 M | ||||
| Net Asset | 273.7 M |
About Lifecore Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.